

ForPatients

by Roche

HER2-Positive Breast Cancer Breast Cancer

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT00833963 H4621g

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The MoTHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).

Genentech, Inc.
Sponsor

N/A
Phase

NCT00833963 H4621g
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>= 18 Years

Healthy Volunteers
No
